China manufacturing approvals expected to provide TruScreen greater market access. Local manufacturing contracts in China under negotiation with expected reduction in component costs. Novel Coronavirus…
TruScreen’s real-time cervical cancer screening device has demonstrated improved sensitivity and specificity targeting pre-cancerous and cancerous cervical cells compared to a Pap test in a…
World Health Organisation’s (WHO) strategy to eliminate cervical cancer worldwide could provide a significant market opportunity for its real-time screening technology for cervical cancer.
